This study was undertaken to evaluate the effects of different rhBMP-2 release profiles in defect areas around dental implants on osseointegration and bone regeneration. Four beagle dogs (13-15 kg) were used. The defect was 3 mm deep and there was a 1 mm gap around the implant. Each of the four implants was installed on the right and left mandibular alveolar ridges. After the implants were placed, experimental groups were applied to the surrounding defect area (n = 8 in each group, the control group was not treated). The inject group was injected with rhBMP-2 solution directly. In the gel group, rhBMP-2 mixed with a hydrogel matrix was applied. In the particle-gel group, rhBMP-2-embedded poly(lactic-co-glycolic acid)(PLGA) microparticles mixed with hydrogel matrix were applied to maintain consistent release. Sequential fluorescent labeling and histological analysis were performed to evaluate the new bone formation and osseointegration in the defect area. In the control group, larger marginal bone loss was detected as compared with the other groups (P < 0.05). The gel group showed significantly higher levels of BIC in the buccal and lingual defect areas compared with the other groups (P < 0.05). New-bone percentages in the inject and gel groups formed more new bone than in the particle-gel and control groups (P < 0.05). Despite the limitations of this study, the use of only hydrogel, which allows early release of rhBMP-2 followed by consistent extended release, showed better bone formation and osseointegration than simple injection or PLGA microparticles with hydrogel matrix.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1748-6041/10/4/045007 | DOI Listing |
J Funct Biomater
December 2024
Department of Orthopedic Surgery, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
This study aimed to investigate the impact of varying the formulation of a specific peptide hydrogel (PepGel) on the release kinetics of rhBMP-2 in vitro. Three PepGel formulations were assessed: (1) 50% / (peptides volume/total volume) PepGel, where synthetic peptides were mixed with crosslinking reagents and rhBMP-2 solution; (2) 67% / PepGel; (3) 80% / PepGel. Each sample was loaded with 12 µg of rhBMP-2 and incubated in PBS.
View Article and Find Full Text PDFGlobal Spine J
December 2024
Swedish Medical Center, Swedish Neuroscience Institute, Seattle, WA, USA.
Study Design: Systematic Review Study.
Objectives: The objective of this study is to assess the cost-effectiveness and cost-utility of rhBMP-2 in spine surgeries.
Methods: PubMed, MEDLINE, OVID and CENTRAL (Cochrane Central Register of Controlled Trials) databases were systematically searched for studies reporting the use of rhBMP-2 for spinal procedures in comparison to autograft and/or allograft and alternative graft materials under consideration of cost-effectiveness, cost-benefit, cost minimization, and/or cost-utility analysis.
Langmuir
December 2024
Division of Craniofacial Function Engineering (Division of Biomaterials Science and Engineering), Tohoku University Graduate School of Dentistry, Sendai 980-8575, Japan.
This study was designed to investigate how the strength of the interaction between octacalcium phosphate (OCP) and modified chondroitin-A sulfate (CS-A), a glycosaminoglycan, regulates the adsorption-desorption of cytokines and subsequently affects the osteoblastic differentiation of mesenchymal stem cells (MSCs) in vitro. The utilization of cytokines produced by cells, such as macrophages, stimulated by the hydrolysis of OCP, is expected to enhance the bone regeneration capacity of the OCP. CS-Na was used to modify CS-A on the OCP immobilized with the amino group through electrostatic interactions.
View Article and Find Full Text PDFJ Physiol Pharmacol
October 2024
Department of Cell Biology and Imaging, Institute of Zoology and Biomedical Research, Jagiellonian University, Cracow, Poland.
Human cell line HS-27A represents an immortalized subpopulation of human stromal cells derived from bone marrow. HS-27A cells meet the criteria set by the International Society of Cell Therapy (ISCT) for the classification as mesenchymal stem cells (MSCs) by expression of surface molecules CD73, CD90, CD105 and HLA-ABC with no expression of CD14, CD31, CD34, CD45 and HLA-DR. We hypothesized that these cells may undergo osteogenesis similar to human bone marrow-derived stromal cells (BMSCs) and serve as a model of osteogenic cell responses under normal and inflammatory conditions.
View Article and Find Full Text PDFWorld J Orthop
November 2024
Department of Basic and Oral Biology, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirao Preto 14040-904, Brazil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!